EGFR and non-small cell lung carcinoma: Clinical trials (JO25567, NEJ026, and RELAY) also found that erlotinib plus vascular endothelial growth factor (VEGF) or VEGF receptor inhibitor significantly prolonged PFS among patients with EGFR‐mutant NSCLC.24, 25, 26